News

BioMarin Pharmaceutical Publishes Follow-Up Data for Hemophilia A Gene Therapy Phase I/II Study

BioMarin Pharmaceutical Publishes Follow-Up Data for Hemophilia A Gene Therapy Phase I/II Study

BioMarin announced the publication in the New England Journal of Medicine of a peer-reviewed article covering up to three years of follow-up data from an ongoing phase II/II study evaluating valoctocogene roxaparvovec, an investigational AAV-based gene therapy for severe hemophilia A. The results demonstrate a "sustained, clinically relevant benefit" to patients from a single infusion of valoctocogene roxaparvovec. With our extensive temperature-controlled storage, packaging, and courier capabilities, Yourway is well equipped to support clinical trials for gene therapies and other advanced therapies.

Back to Index
Media

Upcoming Event

Clinical Trial Supply Europe

March 11-12, 2020
Madrid, Spain
Booth #54

Media

Articles

Agility and Flexibility in a Company That Provides Both Courier and Clinical Packaging Services